Filing Flows › Comparisons › IPSC vs IMCR
Century Therapeutics vs Immunocore Holdings: IPSC and IMCR compared
Century Therapeutics is the larger company: $109M of revenue in its latest quarter (Q1 2025) against $102M for Immunocore Holdings (Q3 2026). Century Therapeutics is growing faster (128× against -1% a year earlier). Century Therapeutics is more profitable, with an operating margin of 67.9% against -13.3%.
Where the money goes: IPSC and IMCR
Century Therapeutics (IPSC) · Q1 2025
Century Therapeutics, Q1 2025: revenue $109M (128× year over year), operating margin 67.9%, net earnings $76.6M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
Immunocore Holdings (IMCR) · Q3 2026
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart follows the revenue to costs, profit and cash.
| Century Therapeutics (IPSC) | Immunocore Holdings (IMCR) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q3 2026 |
| Revenue | $109M | $102M |
| Revenue growth, Y/Y | 128× | -1% |
| Operating margin | 67.9% | -13.3% |
| Net earnings | $76.6M | −$14.2M |
| Net margin | 70.1% | -13.9% |
| Operating cash flow | −$34.6M | $20.1M |
| Free cash flow | — | $17.7M |
| Market value | — | $1.5B |
| Analysts’ mean target | — | $58.33 |
Questions
Which is bigger, Century Therapeutics or Immunocore Holdings?
Century Therapeutics is the larger company: $109M of revenue in its latest quarter (Q1 2025) against $102M for Immunocore Holdings (Q3 2026).
Is Century Therapeutics or Immunocore Holdings growing faster?
Century Therapeutics is growing faster (128× against -1% a year earlier).
Which is more profitable, Century Therapeutics or Immunocore Holdings?
Century Therapeutics is more profitable, with an operating margin of 67.9% against -13.3%.
More: Century Therapeutics earnings · how Century Therapeutics makes money · Immunocore Holdings earnings · how Immunocore Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 15, 2025; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.